1
|
Du Y, Chi X, Wang Y, Cai X, Zeng W, Huo Y, Zhang M, Wang Z, Guo Z, Qiu J, Ma Z, Zhang W, Zhu J, Yang C. Advancements in the ERK1/2 Signaling Pathway Affecting Male Reproduction. FRONT BIOSCI-LANDMRK 2024; 29:23. [PMID: 38287801 DOI: 10.31083/j.fbl2901023] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/06/2023] [Revised: 09/05/2023] [Accepted: 09/27/2023] [Indexed: 01/31/2024]
Abstract
Male infertility, age-related changes, and tumors have been increasingly studied in the field of male reproductive health due to the emergence of environmental stressors, declining fertility rates, and aging populations. Numerous studies have demonstrated that the ERK1/2 signaling pathway plays a significant role in male reproduction. The ERK1/2 pathway is associated with several signaling pathways and has a complex interplay that influences the spermatogenic microenvironment, sperm viability, gonadal axis regulation, as well as resistance to testicular aging and tumors. Moreover, the ERK1/2 pathway directly or indirectly regulates testicular somatic cells, which are crucial for maintaining spermatogenesis and microenvironment regulation. Given the critical role of the ERK1/2 signaling pathway in male reproductive health, comprehensive exploration of its multifaceted effects on male reproduction and underlying mechanisms is necessary. This study aims to provide a solid foundation for in-depth research in the field of male reproduction and further enhance the reproductive health of males.
Collapse
Affiliation(s)
- Yikuan Du
- Central Laboratory, The Tenth Affiliated Hospital of Southern Medical University, 523059 Dongguan, Guangdong, China
| | - Xianhong Chi
- Dongguan Key Laboratory of Chronic Inflammatory Diseases, The First Dongguan Affiliated Hospital, Guangdong Medical University, 523808 Dongguan, Guangdong, China
| | - Yuni Wang
- Dongguan Key Laboratory of Chronic Inflammatory Diseases, The First Dongguan Affiliated Hospital, Guangdong Medical University, 523808 Dongguan, Guangdong, China
| | - Xiaolin Cai
- Dongguan Key Laboratory of Chronic Inflammatory Diseases, The First Dongguan Affiliated Hospital, Guangdong Medical University, 523808 Dongguan, Guangdong, China
| | - Wenqi Zeng
- Dongguan Key Laboratory of Chronic Inflammatory Diseases, The First Dongguan Affiliated Hospital, Guangdong Medical University, 523808 Dongguan, Guangdong, China
| | - Yuying Huo
- Dongguan Key Laboratory of Chronic Inflammatory Diseases, The First Dongguan Affiliated Hospital, Guangdong Medical University, 523808 Dongguan, Guangdong, China
| | - Mengting Zhang
- Dongguan Key Laboratory of Chronic Inflammatory Diseases, The First Dongguan Affiliated Hospital, Guangdong Medical University, 523808 Dongguan, Guangdong, China
| | - Zhenjie Wang
- Dongguan Key Laboratory of Chronic Inflammatory Diseases, The First Dongguan Affiliated Hospital, Guangdong Medical University, 523808 Dongguan, Guangdong, China
| | - Zhuoming Guo
- Dongguan Key Laboratory of Chronic Inflammatory Diseases, The First Dongguan Affiliated Hospital, Guangdong Medical University, 523808 Dongguan, Guangdong, China
| | - Jingnan Qiu
- Dongguan Key Laboratory of Chronic Inflammatory Diseases, The First Dongguan Affiliated Hospital, Guangdong Medical University, 523808 Dongguan, Guangdong, China
| | - Zhendong Ma
- Dongguan Key Laboratory of Chronic Inflammatory Diseases, The First Dongguan Affiliated Hospital, Guangdong Medical University, 523808 Dongguan, Guangdong, China
| | - Weichui Zhang
- Dongguan Key Laboratory of Chronic Inflammatory Diseases, The First Dongguan Affiliated Hospital, Guangdong Medical University, 523808 Dongguan, Guangdong, China
| | - Jinfeng Zhu
- Dongguan Key Laboratory of Chronic Inflammatory Diseases, The First Dongguan Affiliated Hospital, Guangdong Medical University, 523808 Dongguan, Guangdong, China
| | - Chun Yang
- Dongguan Key Laboratory of Chronic Inflammatory Diseases, The First Dongguan Affiliated Hospital, Guangdong Medical University, 523808 Dongguan, Guangdong, China
- Dongguan Key Laboratory of Stem Cell and Regenerative Tissue Engineering, Guangdong Medical University, 523808 Dongguan, Guangdong, China
| |
Collapse
|
2
|
Du Y, Guo J, Zhou Y, Yan S, Xu B, Wang Y, Lu D, Ma Z, Chen Q, Tang Q, Zhang W, Zhu J, Huang Y, Yang C. Revealing the Mechanisms of Byu dMar 25 in the Treatment of Alzheimer's Disease through Network Pharmacology, Molecular Docking, and In Vivo Experiment. ACS Omega 2023; 8:25066-25080. [PMID: 37483184 PMCID: PMC10357573 DOI: 10.1021/acsomega.3c01683] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 03/15/2023] [Accepted: 05/25/2023] [Indexed: 07/25/2023]
Abstract
BACKGROUND Alzheimer's disease (AD) is the most common neurodegenerative disease, severely reducing the cognitive level and life quality of patients. Byu dMar 25 (BM25) has been proved to have a therapeutic effect on AD. However, the pharmacological mechanism is still unclear. Therefore, this study aims to reveal the potential mechanism of BM25 affecting AD from the perspective of network pharmacology and experimental validation. METHODS The potential active ingredients of BM25 were obtained from the TCMSP database and literature. Possible targets were predicted using SwissTargetPrediction tools. AD-related genes were identified by using GeneCards, OMIM, DisGeNET, and Drugbank databases. The candidate genes were obtained by extraction of the intersection network. Additionally, the "drug-target-disease" network was constructed by Cytoscape 3.7.2 for visualization. The PPI network was constructed by the STRING database, and the core network modules were filtered by Cytoscape 3.7.2. Enrichment analysis of GO and KEGG was carried out in the Metascape platform. Ledock software was used to dock the critical components with the core target. Furthermore, protein levels were evaluated by immunohistochemistry. RESULTS In this study, 112 active components, 1112 disease candidate genes, 3084 GO functions, and 277 KEGG pathways were obtained. Molecular docking showed that the effective components of BM25 in treating AD were β-asarone and hydroxysafflor yellow A. The most important targets were APP, PIK3R1, and PIK3CA. Enrichment analysis indicated that the Golgi genetic regulation, peroxidase activity regulation, phosphatidylinositol 3-kinase complex IA, 5-hydroxytryptamine receptor complexes, cancer pathways, and neuroactive ligand-receptor interactions played vital roles against AD. The rat experiment verified that BM25 affected PI3K-Akt pathway activation in AD. CONCLUSIONS This study reveals the mechanism of BM25 in treating AD with network pharmacology, which provides a foundation for further study on the molecular mechanism of AD treatment.
Collapse
Affiliation(s)
- Yikuan Du
- Central
Laboratory, The Tenth Affiliated Hospital
of Southern Medical University, Dongguan 523059, China
| | - Jinyan Guo
- Dongguan
Key Laboratory of Chronic Inflammatory Diseases, The First Dongguan Affiliated Hospital, Guangdong Medical University, Dongguan 523000, China
- Dongguan
Key Laboratory of stem cell and regenerative tissue engineering, Guangdong Medical University, Dongguan 523808, China
| | - Yuqi Zhou
- Dongguan
Key Laboratory of Chronic Inflammatory Diseases, The First Dongguan Affiliated Hospital, Guangdong Medical University, Dongguan 523000, China
- Dongguan
Key Laboratory of stem cell and regenerative tissue engineering, Guangdong Medical University, Dongguan 523808, China
| | - Simin Yan
- Dongguan
Key Laboratory of Chronic Inflammatory Diseases, The First Dongguan Affiliated Hospital, Guangdong Medical University, Dongguan 523000, China
- Dongguan
Key Laboratory of stem cell and regenerative tissue engineering, Guangdong Medical University, Dongguan 523808, China
| | - Bijun Xu
- Dongguan
Key Laboratory of Chronic Inflammatory Diseases, The First Dongguan Affiliated Hospital, Guangdong Medical University, Dongguan 523000, China
- Dongguan
Key Laboratory of stem cell and regenerative tissue engineering, Guangdong Medical University, Dongguan 523808, China
| | - Yuni Wang
- Dongguan
Key Laboratory of Chronic Inflammatory Diseases, The First Dongguan Affiliated Hospital, Guangdong Medical University, Dongguan 523000, China
- Dongguan
Key Laboratory of stem cell and regenerative tissue engineering, Guangdong Medical University, Dongguan 523808, China
| | - Duoduo Lu
- Dongguan
Key Laboratory of Chronic Inflammatory Diseases, The First Dongguan Affiliated Hospital, Guangdong Medical University, Dongguan 523000, China
- Dongguan
Key Laboratory of stem cell and regenerative tissue engineering, Guangdong Medical University, Dongguan 523808, China
| | - Zhendong Ma
- Dongguan
Key Laboratory of Chronic Inflammatory Diseases, The First Dongguan Affiliated Hospital, Guangdong Medical University, Dongguan 523000, China
- Dongguan
Key Laboratory of stem cell and regenerative tissue engineering, Guangdong Medical University, Dongguan 523808, China
| | - Qianwen Chen
- Dongguan
Key Laboratory of Chronic Inflammatory Diseases, The First Dongguan Affiliated Hospital, Guangdong Medical University, Dongguan 523000, China
- Dongguan
Key Laboratory of stem cell and regenerative tissue engineering, Guangdong Medical University, Dongguan 523808, China
| | - Qibin Tang
- Dongguan
Key Laboratory of Chronic Inflammatory Diseases, The First Dongguan Affiliated Hospital, Guangdong Medical University, Dongguan 523000, China
- Dongguan
Key Laboratory of stem cell and regenerative tissue engineering, Guangdong Medical University, Dongguan 523808, China
| | - Weichui Zhang
- Dongguan
Key Laboratory of Chronic Inflammatory Diseases, The First Dongguan Affiliated Hospital, Guangdong Medical University, Dongguan 523000, China
- Dongguan
Key Laboratory of stem cell and regenerative tissue engineering, Guangdong Medical University, Dongguan 523808, China
| | - Jinfeng Zhu
- Dongguan
Key Laboratory of Chronic Inflammatory Diseases, The First Dongguan Affiliated Hospital, Guangdong Medical University, Dongguan 523000, China
- Dongguan
Key Laboratory of stem cell and regenerative tissue engineering, Guangdong Medical University, Dongguan 523808, China
| | - Yixing Huang
- Dongguan
Key Laboratory of Chronic Inflammatory Diseases, The First Dongguan Affiliated Hospital, Guangdong Medical University, Dongguan 523000, China
- Dongguan
Key Laboratory of stem cell and regenerative tissue engineering, Guangdong Medical University, Dongguan 523808, China
| | - Chun Yang
- Dongguan
Key Laboratory of Chronic Inflammatory Diseases, The First Dongguan Affiliated Hospital, Guangdong Medical University, Dongguan 523000, China
- Dongguan
Key Laboratory of stem cell and regenerative tissue engineering, Guangdong Medical University, Dongguan 523808, China
| |
Collapse
|